<DOC>
	<DOCNO>NCT02532049</DOCNO>
	<brief_summary>This clinical trial healthy volunteer administer one two experimental malaria vaccine . ChAd Pfs-IMX313 either administer alone MVA Pfs25-IMX313 prime-boost regime . All vaccine administer intramuscularly . Group 1 receive one dose ChAd63 Pfs25-IMX313 5x10^9 vp . Group 2A receive one dose ChAd63 Pfs-IMX313 5x10^10 vp . Group 2B receive one dose ChAd63 Pfs-IMX313 5x10^10 vp one dose MVA Pfs25-IMX313 1x10^8 pfu eight week later . Group 2C receive one dose ChAd63 Pfs25-IMX313 5x10^10 vp one dose MVA Pfs25-IMX313 2x10^8 pfu eight week later . The study assess safety vaccination , immune response vaccination . Immune responses measure test blood sample . Healthy volunteer recruit Oxford Southampton , England .</brief_summary>
	<brief_title>A Clinical Trial Assess Safety Immunogenicity New Malaria Vaccine Candidates ChAd63 Pfs25-IMX313 MVA Pfs25-IMX313</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>The volunteer must satisfy follow criterion eligible study : Healthy adult age 18 50 year Able willing ( Investigator 's opinion ) comply study requirement Willing allow investigator discuss volunteer 's medical history General Practitioner For female , willingness practice continuous effective contraception ( see ) study negative pregnancy test day ( ) screen vaccination Agreement refrain blood donation course study Provide write informed consent The volunteer may enter study follow apply : Participation another research study involve receipt investigational product 30 day precede enrolment , plan use study period Prior receipt investigational malaria vaccine investigational vaccine likely impact interpretation trial data . Administration immunoglobulins and/or blood product within three month precede plan administration vaccine candidate Any confirm suspected immunosuppressive immunodeficient state , include HIV infection ; asplenia ; recurrent , severe infection chronic ( 14 day ) immunosuppressant medication within past 6 month ( inhaled topical steroid allow ) History allergic disease reaction likely exacerbate component vaccine , e.g . egg product . Any history anaphylaxis relation vaccination Pregnancy , lactation willingness/intention become pregnant study History cancer ( except basal cell carcinoma skin cervical carcinoma situ ) History serious psychiatric condition likely affect participation study Any serious chronic illness require hospital specialist supervision Suspected known current alcohol abuse define alcohol intake great 42 unit every week Suspected known inject drug abuse 5 year precede enrolment Seropositive hepatitis B surface antigen ( HBsAg ) Seropositive hepatitis C virus ( antibody HCV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Immune Response</keyword>
</DOC>